Reduced anti-TNFα autoantibody levels coincide with flare in systemic lupus erythematosus

Journal of Autoimmunity

Volumn 22, Issue 4, 2004, Pages 315-323

  Sjöwall, Christopher ^a   Ernerudh, Jan ^a   Bengtsson, Anders A ^b   Sturfelt, Gunnar ^b   Skogh, Thomas ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anti cytokine antibodies; Disease activity; Immunoregulation; SLEDAI; Systemic lupus erythematosus; Tumour necrosis factor

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; CYTOKINE; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE CONTROL; DISEASE EXACERBATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOREGULATION; MALE; PATHOGENESIS; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; CASE-CONTROL STUDIES; CHILD; COMPLEMENT C1Q; COMPLEMENT C3; CYTOKINES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 16544381633     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaut.2004.02.003     Document Type: Article

References (42)

1. Cope A.P. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol. 10:1998;669-676
2. Ward P.A., Lentsch A.B. Endogenous regulation of the acute inflammatory response. Mol Cell Biochem. 234/235:2002;225-228
3. Holloway A.F., Rao S., Shannon M.F. Regulation of cytokine gene transcription in the immune system. Mol Immunol. 38:2002;567-580
4. Kirou K.A., Crow M.K. New pieces to the SLE cytokine puzzle. Clin Immunol. 91:1999;1-5
5. Aringer M., Smolen J.S. Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus. Arthritis Res Ther. 5:2003;172-177
6. Leng Q., Bentwich Z. Beyond self and nonself: fuzzy recognition of the immune system. Scand J Immunol. 56:2002;224-232
7. Funauchi M., Ikoma S., Enomoto H., Horiuchi A. Decreased Th1-like and increased Th2-like cells in systemic lupus erythematosus. Scand J Rheumatol. 27:1998;219-224
8. Horwitz D.A., Gray J.D., Behrendsen S.C., Kubin M., Rengaraju M., Ohtsuka K., et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum. 41:1998;838-844
9. Theofilopoulos A.N., Koundouris S., Kono D.H., Lawson B.R. The role of IFN-γ in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res. 3:2001;136-141
10. Beebe A.M., Cua D.J., de Waal-Malefyt R. The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS). Cytokine Growth Factor Rev. 13:2002;403-412
11. Rönnblom L., Alm G.V. Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther. 5:2003;68-75
12. Bendtzen K., Hansen M.B., Ross C., Svenson M. Cytokine autoantibodies. Peter J.B., Shoenfeldt Y. Autoantibodies. 1996;209-216 Elsevier, Amsterdam
13. Hellmich B., Csernok E., Schatz H., Gross W.L., Schnabel A. Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus. Arthritis Rheum. 46:2002;2384-2391
14. Taylor P.C. Anti-TNFα therapy for rheumatoid arthritis: an update. Intern Med. 42:2003;15-20
15. Graudal N.A., Svensson M., Tarp U., Garred P., Jurik A.G., Bendtzen K. Autoantibodies against interleukin-1α in rheumatoid arthritis: association with long term radiographic outcome. Ann Rheum Dis. 61:2002;598-602
16. Elkarim R.A., Dahle C., Mustafa M., Press R., Zou L.P., Ekerfelt C., et al. Recovery from Guillain-Barré syndrome is associated with increased levels of neutralizing autoantibodies to interferon-γ Clin Immunol Immunopathol. 88:1998;241-248
17. Meager A., Wadhwa M., Dilger P., Bird C., Thorpe R., Newsom-Davis J., et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol. 132:2003;128-136
18. Takemura H., Suzuki H., Yoshizaki K., Ogata A., Takamichi Y., Akama T., et al. Anti-interleukin-6 autoantibodies in rheumatic diseases: Increased frequency in the sera of patients with systemic sclerosis. Arthritis Rheum. 35:1992;940-943
19. Steel D.M., Whitehead A.S. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today. 15:1994;81-88
20. Pepys M.B., Lanham J.G., De Beer F.C. C-reactive protein in SLE. Clin Rheum Dis. 8:1982;91-103
21. Sjöwall C., Eriksson P., Almer S., Skogh T. Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjögren's syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun. 19:2002;155-160
22. Evans M., Abdou N.I. Anti-interleukin-6 and soluble interleukin-6 receptor in systemic lupus erythematosus. Lupus. 3:1994;161-166
23. Tsuchiyama L., Wong T., Kieran J., Boyle P., Penza D., Wetzel G.D. Comparison of anti-TNFα autoantibodies in plasma from EBV transformed lymphocytes of autoimmune and normal individuals. Hum Antibodies Hybridomas. 6:1995;73-76
24. von Wussow P., Jakschies D., Hartung K., Deicher H. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol Int. 8:1988;225-230
25. Slavikova M., Schmeisser H., Kontsekova E., Mateicka F., Borecky L., Kontsek P. Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia. J Interferon Cytokine Res. 23:2003;143-147
26. Gladman D.D., Ibanez D., Urowitz M.B. Systemic lupus erythematosus activity index 2000. J Rheumatol. 29:2002;288-291
27. Burger D., Dayer J.M. Cytokines, acute-phase proteins, and hormones: IL-1 and TNF-α production in contact-mediated activation of monocytes by T lymphocytes. Ann N Y Acad Sci. 966:2002;464-473
28. Keystone E., Wherry J., Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 24:1998;629-639
29. Llorente L., Richaud-Patin Y., Garcia-Padilla C., Claret E., Jakez-Ocampo J., Cardiel M.H., et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 43:2000;1790-1800
30. Gary-Gouy H., Lebon P., Dalloul A.H. Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines. J Interferon Cytokine Res. 22:2002;653-659
31. Mohan N., Edwards E.T., Cupps T.R., Oliverio P.J., Sandberg G., Crayton H., et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum. 44:2001;2862-2869
32. Shakoor N., Michalska M., Harris C.A., Block J.A. Drug-induced lupus erythematosus associated with etanercept therapy. Lancet. 359:2002;579-580
33. Alves-Rosa M.F., Palermo M.S., Isturiz M.A. Enhancement of immune complex clearance by TNFα in a murine model. Clin Immunol Immunopathol. 89:1998;214-221
34. Jacob C.O., Hwang F., Lewis G.D., Stall A.M. Tumor necrosis factor alpha in murine systemic lupus erythematosus disease models: implications for genetic predisposition and immune regulation. Cytokine. 3:1991;551-561
35. Charles P.J., Smeenk R.J., De Jong J., Feldmann M., Maini R.N. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 43:2000;2383-2390
36. Pisetsky D.S. Tumor necrosis factor α blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum. 43:2000;2381-2382
37. Aringer M., Steiner G., Graninger W., Smolen J.S. Role of tumor necrosis factor α potential benefit of tumor necrosis factor blockade treatment in systemic lupus erythematosus. Arthritis Rheum. 44:2001;1721-1722
38. Tsunawaki S., Sporn M., Ding A., Nathan C. Deactivation of macrophages by transforming growth factor-β Nature. 334:1988;260-262
39. Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 175:1992;323-329
40. MacEwan D.J. TNF ligands and receptors - a matter of life and death. Br J Pharmacol. 135:2002;855-875
41. Studnicka-Benke A., Steiner G., Petera P., Smolen J.S. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol. 35:1996;1067-1074
42. Gabay C., Cakir N., Moral F., Roux-Lombard P., Meyer O., Dayer J.M., et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol. 24:1997;303-308